Sun Pharma is expected to report healthy double-digit revenue growth in the March quarter, supported by strong performance in speciality drugs, domestic formulations and emerging markets. Brokerages expect the company's US speciality portfolio, particularly newer products such as Unloxcyt and Leqselvi, to remain key growth drivers during the quarter.According to Motilal Oswal, Sun Pharma is likely to report around 13% year-on-year (YoY) revenue growth in Q4FY26. The brokerage expects growth to be driven by strong performance in India, emerging markets and rest-of-world markets, along with incremental recovery in the US business.Motilal Oswal said the recent launch of Unloxcyt is expected to support growth in the US market. The brokerage also expects Sun Pharma’s domestic formulations business to continue outperforming the broader pharmaceutical industry.It estimates domestic formulation sales growth of around 14% year-on-year during the quarter, supported by new launches and continued traction in products such as Ilumya. Emerging markets and rest-of-world markets are also expected to remain strong contributors.Motilal Oswal expects 20% growth in emerging markets and 17% growth in rest-of-world revenues during the quarter, driven by branded generics and innovative products.PL Capital said speciality and domestic businesses are likely to remain the primary growth engines for Sun Pharma. The brokerage expects moderate EBITDA expansion while highlighting that the continued ramp-up in the speciality portfolio remains a key monitorable.Kotak Equities expects Sun Pharma's overall sales to rise around 12% YoY in the fourth quarter. The brokerage estimates US sales at around $500 million during the quarter, reflecting sequential growth of 5%, mainly because of higher speciality drug sales.Kotak expects the company's global speciality business revenue to reach around $400 million during the quarter, implying 36% YoY growth. The brokerage said growth is likely to be led by the Unloxcyt launch, improving traction in Leqselvi and rising prescriptions for Ilumya.Kotak also expects India business growth of around 13% YoY and 16% growth in emerging markets and rest-of-world markets. On profitability, analysts expect margins to remain broadly stable despite higher research and development spending.Kotak estimates Sun Pharma's gross margins at around 79.3%, marginally lower YoY. The brokerage sees R&D expenditure rise to around 6.4% of sales during the quarter.EBITDA is estimated at around Rs 3,880 crore, reflecting growth of approximately 13% YoY. Kotak expects EBITDA margin at 26.6%, broadly stable compared with the corresponding quarter last year.Investors will closely monitor management commentary around speciality product ramp-up, US regulatory developments and pricing trends in key markets.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)